Citius Pharmaceuticals Inc. has provided an update on its advanced development programs in the biopharmaceutical sector. The company highlighted the launch of LYMPHIR (denileukin diftitox-cxdl) in December 2025 for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. LYMPHIR is the first marketed product by Citius Oncology, Inc. (NASDAQ: CTOR), which became a stand-alone public company in August 2024 and remains a majority-owned subsidiary of Citius Pharmaceuticals. Other programs featured include Mino-Lok®, a treatment designed to salvage infected catheters causing central line-associated bloodstream infections (CLABSI), which has completed a Phase 3 trial with positive topline data, and Halo-Lido, a prescription therapy in development for hemorrhoids, which has completed a Phase 2b trial. The presentation notes that Citius Oncology has established a shared management services agreement with Citius Pharmaceuticals to support operational efficiency. You can access the full presentation through the link below.